ASCENDING MULTIDOSE CI PHARM STUDY VPA-985 PTS W/CHRONIC CONGESTIVE HEART FAILURE

伴有慢性充血性心力衰竭的升序多剂量 CI 药物研究 VPA-985 PTS

• 批准号: 6114182
• 负责人: WILLIAM T ABRAHAM
• 金额: $ 3.22万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6114182
• 关键词: clinical research; clinical trial phase I; congestive heart failure; drug screening /evaluation; heart disorder chemotherapy; hormone inhibitor; hormone receptor; human subject; human therapy evaluation; pharmacokinetics; vasopressins

VPA-985 is a nonpeptide, orally active competitive vasopressin receptor antagonist, specific for the V2 receptor subtype. This study is designed to evaluate the safety, tolerance, pharmacokinetics and pharmacodynamics of multiple oral doses of VPA-985 in patients with chronic congestive heart failure (CHF). In addition, a preliminary assessment will be made of the changes in the signs and symptoms of excess fluid volume.

VPA-985是一种非肽类口服活性竞争性血管加压素受体拮抗剂，对V2受体亚型具有特异性。本研究旨在评价VPA-985多次口服给药在慢性充血性心力衰竭（CHF）患者中的安全性、耐受性、药代动力学和药效学。此外，还将对液体过多的体征和症状的变化进行初步评估。